Key risk factors for development of drug-induced liver injury (DILI), especially genetic factors like HLA associations, are the focus of this lecture. Speakers will explore other genetic risk factors that may contribute to DILI and discuss recent data showing how the non-HLA gene PTPN22 may contribute to DILI due to the use of a number of different drugs.
Harmful alcohol use accounts for three million annual global deaths. Experts discuss the global health burden of alcohol-related liver disease (ALD), reporting on ALD’s impact in Africa, Latin America and Asia, region-specific factors that promote or hinder solutions and how forthcoming AASLD guidance on ALD may serve as a template to implement effective prevention and treatment strategies worldwide.
Manhal Izzy, Lisa B. VanWagner, Grace Lin, Mario Altieri, James Y. Findlay, Jae K. Oh, Kymberly Watt, Samuel S. Lee, the Cirrhotic Cardiomyopathy Consortium: The Cirrhotic Cardiomyopathy Consortium is a multidisciplinary international group whose focus is to improve the understanding of cirrhotic cardiomyopathy, its management and outcomes – 11 November 2019
Anoop N. Koshy, Omar Farouque, Paul Calafiore, Paul J. Gow – 11 November 2019
The Diversity and Inclusion Committee promotes health disparities research and efforts to improve health outcomes among ethnic and racial groups who carry a higher burden of liver disease. Based on positive feedback from the 2018 workshop on Ethnic and Racial Disparities in Liver Disease, this two-hour workshop reviews current programmatic efforts to eliminate disparate outcomes in liver disease and liver transplantation.
Acute on Chronic Liver Failure (ACLF) is a well-recognized rapid course of liver disease that can have devastating consequences on patients. At this symposium, faculty will discuss ACLF’s common triggers and explore current perspectives of management in the context of these triggering events. Topics covered include microbiome analysis to identify high-risk patients and the role of transplantation.
Review data from ongoing clinical trials for alcoholic hepatitis, explore the role of early liver transplantation and discuss the management of alcohol use disorder in patients with alcoholic hepatitis and acute on chronic liver failure. Topics covered include trial design considering standards of care and liver transplantation’s emerging role and subject recruitment challenges for clinical trials in alcoholic hepatitis.
Immunosuppression in the liver transplant setting includes multiple drugs aimed at predetermined trough levels, adjusted to time after transplantation. Excellent graft and patient survival supports immunosuppression, but there may be significant short- and long-term risks. At this presentation, experts will discuss clinical approaches to immunosuppression in liver transplant patients, including biomarkers used for safe personalization of this process.
Discuss the current state of the ABIM Maintenance of Certification (MOC) program for gastroenterologists and transplant hepatologists at this update. Speakers will review the expense, time commitment and relevance of this program’s requirements; current MOC requirements in the program; the means to meet these requirements; progress made in addressing concerns from ABIM diplomats; and alternative pathways to board recertification.
Value-Based Arrangements are increasingly becoming part of the healthcare landscape. The goal of this program is to educate and empower hepatologists to be valuable contributors to the success of these new arrangements and play an active role in developing and implementing beneficial approaches.